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Kallikreins play an important role in tumour microenvironment and as cancer biomarkers in different cancer entities. Previous studies
suggested an upregulation of KLK10 and KLK6 in pancreatic ductal adenocarcinoma (PDAC). Therefore, we evaluated the
clinicopathological role of these kallikreins and their value as biomarkers in PDAC.
Differential expression was validated by DNA-microarrays and immunohistochemistry in normal and malignant pancreatic tissues.
Sera concentrations of both kallikreins were evaluated using ELISA. In silico analysis of possible protein interactions and gene silencing
of KLK10 in vitro using siRNAs gave further insights in the pathomechanisms.
Gene expression analysis and immunohistochemistry demonstrated a strong expression for KLK10 and KLK6 in PDAC. Statistical
analysis showed that co-expression of these kallikreins correlated with an R1-resection status (P¼0.017) and worse outcome for
overall survival (P¼0.031). Multivariate analysis proofed that co-expression is an independent prognostic factor for survival
(P¼0.043). Importantly, KLK10 knockdown in AsPC-1 cells significantly reduced cell migration, whereas computational analysis
suggested interaction of KLK6 with angiogenetic factors as an important mechanism.
Co-expression of KLK10 and KLK6 plays an unfavourable role in PDAC. Our results suggest that this effect is likely mediated by an
interaction with the factors of the extracellular matrix and enhancement of cancer cell motility.
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Pancreatic ductal adenocarcinoma (PDAC) is one of the most
aggressive cancers with an incidence rate of 6.3/100000 (Lowenfels
and Maisonneuve, 2006; Jemal et al, 2008). It is characterised by
early metastasising and aggressive, infiltrative growth along the
endothelium basement membrane and neurons (Eccles and Welch,
2007). This leaves more than 85% of the patients inoperable at the
time of diagnosis. Unfortunately pancreatic carcinoma also shows
an unsatisfactory response to oncological treatment (Wolff et al,
2000). This demonstrates the need for new therapeutic approaches
and also for biomarkers, which make early diagnosis possible.
Recently, we (Grutzmann et al, 2003) and others (Iacobuzio-
Donahue et al, 2003; Yousef et al, 2004) showed that human
kallikrein 10 and human kallikrein 6 are among the most highly
and specifically overexpressed genes in pancreatic cancer com-
pared with normal and benign pancreas tissues.
KLK10 and KLK6 are members of the kallikrein family of 15
known proteases in humans, which play an emerging role in
tumour microenvironment, invasion and angiogenesis (Borgono
and Diamandis, 2004). Kallikreins exert this function as secreted
trypsin and chymotrypsin-like proteases by degradation of the
extracellular matrix, which is an important reservoir for cytokines
and growth factors such as VEGF, TGF-b and kininogens (Borgono
and Diamandis, 2004). Moreover, KLK3, also known as prostate-
specific antigen, is of great clinical value as a serological marker in
prostate cancer (Borgono and Diamandis, 2004). Other members
of the kallikrein family might also have a utility in screening of
malignancies, like KLK11 and KLK6 for ovarian cancer (Diamandis
et al, 2003; McIntosh et al, 2007). This leaves kallikreins as
advantageous candidate genes for diagnosis and therapy in
pancreatic cancer. Therefore, the aim of this study was to evaluate
the clinicopathological role of these kallikreins and their value as
biomarkers in PDAC.
KLK10, also known as the normal epithelial cell-specific 1 is one
of the newly identified members of the kallikrein family. Its role in
carcinogenesis is unsolved as it is downregulated in some tumours
such as breast cancer and acute lymphoblastic leukaemia, whereas
overexpressed in ovarian, prostate or renal cancer (Luo et al, 2003;
Petraki et al, 2003, 2006; Zhang et al, 2006). Unfortunately, the
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sfunction of KLK10 protein remains poorly documented, neither
the activators nor the substrates for KLK10 are actually known
(Zhang et al, 2006). KLK6, or protease M, is highly expressed in
several malignancies like ovarian, breast, colon or gastric cancer.
It is correlated with lymphatic invasion and poor prognosis in
gastric cancer (Yousef et al, 2004; Nagahara et al, 2005). KLK6
might exert this effect by the degradation of matrix proteins
and thereby the augmentation of cancer cell motility and
proliferation (Ghosh et al, 2004).
In this study, we show that kallikrein 10 and 6 demonstrate a
strong protein expression in pancreatic carcinoma and are
associated with poor patient prognosis and R1 resection status
and thereby might contribute to the aggressive character of this
malignancy.
The results indicate that this effect is most likely mediated by the
interaction of KLK6 with factors of the extracellular matrix and the
enhancement of cancer cell motility by KLK10.
MATERIALS AND METHODS
Patients and demographic data
For immunohistochemical analysis we used samples from 54
patients, operated from July 1996 until December 2003. None of
the patients received adjuvant chemotherapy prior to operation.
The eligibility criterion was a histologically confirmed PDAC. A
positive microscopic resection margin (R1) was operationally
defined as at least one cancer cell within 1mm of any surface of the
resected specimen. We included patients with the finding of
metastases to the intra-aortocaval lymph nodes. Previous reports
have shown that these metastases should not exclude patients in
good condition from oncologic resection of the PDAC (Shrikhande
et al, 2007). Relevant patient characteristics are summarised in
Table 1.
For serum-ELISA several panels of sera were selected from 130
healthy donors, eight patients with benign tumours, 34 with
inflammatory diseases and 28 patients with malignant diseases
(Table 2). All sera were from patients treated at the University
Hospital Dresden, Germany and University Hospital Schleswig–
Holstein, Germany. All patients had given informed consent.
Construction of a virtual subarray and bioinformatic
analysis
For the construction of the virtual subarray we used data obtained
from the U133 A/B Affymetrix GeneChip using extracted RNA
from microdissected tissue as described earlier (Pilarsky et al,
2008).
The Cel Files obtained from the Affymetrix MAS 5.0 software
were used for further analysis. The files were loaded into dCHIP
1.3 (www.dchip.org) then normalised, and expression values as
well as absolute calls were calculated using the PM/MM model
(Grutzmann et al, 2003). We scored genes as differentially
expressed if they displayed a fold change 42. To identify signature
genes we used the method described elsewhere (Grutzmann et al,
2004). Datasets are accessible (Arrayexpress E-MEXP-1121 and
E-MEXP-950).
Immunohistochemistry study and evaluation
Immunostaining was carried out on paraffin-embedded tissue
sections by streptavidin—biotin–peroxidase complex method
using polyclonal antibodies for KLK6 and KLK10 (1:150). The
ductal epithelium and the Langerhans’ islets served as positive
controls for both kallikreins (Petraki et al, 2001, 2002a, 2003).
Negative controls were performed for all studied tissues by
omitting the primary antibody (KLK6 and KLK10) or by replacing
it by non-immune serum (dilution 1:500) (see Supplementary
Data 1).
All sections were examined by one observer (CDP) blinded to
both clinical and pathological data. Protein expression in PDACs
was quantified using a visual grading system with a range between
0 and 2, based on the intensity and the proportion of positive
tumour cells on the studied section: 0¼no immunoexpression or
weak staining in any proportion of the cancerous tissue, or
moderate expression in o/¼5% of the cancerous tissue,
1¼moderate staining in 5–50% of the cancerous tissue,
2¼moderate staining in 450% of the cancerous tissue or strong
staining in any proportion of the cancerous tissue. According to
staining intensity, cancers were classified as low, medium or high
expressing tumours. Coexpression of both KLKs was defined as
strong if the sample showed strong expression for both KLKs (2/2)
and/or at least showed moderate expression for one KLK (2/1).
KLK6 and 10 immunoexpression were also screened in the normal
pancreatic parenchyma (acinar, ductal and endocrine cells) and in
the ampulla of Vater region of the small intestine.
Patient serum selection and ELISA for kallikrein
measurement in serum
ELISA-type immunofluorometric procedures developed in-house
were used to measure KLK6 and 10 levels in these sera. Assays used
in this study were of the ‘sandwich’ type with the primary antibody
used for capture and the secondary one for detection. Mono-
clonal–monoclonal combinations were used in this study. All
ELISAs were tested negative for cross-reactivity against other
kallikreins. Assay precision within the dynamic range was o10%.
These assays were standardised with recombinant proteins
produced in yeast or mammalian expression systems. More details
about the kallikrein ELISA have recently been published (Shaw and
Diamandis, 2007).
Protein interaction prediction
To evaluate the interactions we queried databases with known
protein–protein interactions such as NetPro (www.molecular
connections.com), SCOPPI (www.scoppi.org) and HPRD
(www.hprd.org) and compared them to our data. To find possible
novel interactions we used structure- and sequence-based
prediction of protein interactions as described earlier (Altschul
et al, 1997; Mishra et al, 2006; Dawelbait et al, 2007).
Cell culture and transfection conditions
The AsPC-1 cell line (ATCC Number CRL-1682), established from
malignant ascites of a 62-year-old female caucasian, was used for
this study. Cells were grown in RPMI-1640 (Invitrogen, Karlsruhe,
Germany) with 2mML -glutamine, 1mM sodium pyruvate, 4.5gl
 1
glucose and 10% FCS in a humidified atmosphere containing 5%
CO2 at 371C. AsPC-1 cells (50000) in media with 1% FCS were
transfected with 600ng of siRNA using oligofectamine (Invitrogen
GmbH, Karlsruhe, Germany). Target sense sequences that
effectively mediated silencing were as follows: KLK10.1 (UACAUG
UCCUGGAUCAAUA) and KLK10.2 (UGACGUGCCUACCUCUU
AG) (all from MWG Biotech, Ebersberg, Germany). Knockdown
was confirmed by RT–PCR and western blot. siRNA against the
green fluorescent protein (GGCUACGUCCAGGAGCGCACC)
served as a negative control. For RT–PCR the following cell lines
were used: Capan-1 (ATCC No. HTB-79), Capan-2 (ATCC No.
HTB-80), MiaPaCa-2 (CRL-1420), Panc1 (ECACC No. 7092802),
BXPC3 (CRL-1687) and Panc 89, Colo357, PancTUI, PT45P1
(all from Professor H Kalthoff, Kiel, Germany, (Sipos et al, 2003)).
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Using RNeasy Mini Kit (Qiagen, Hilden, Germany) we isolated
total RNA and subjected 500ng to cDNA synthesis using random
primer and SuperScript II (Invitrogen GmbH, Karlsruhe,
Germany). Of the synthesised cDNA 2% were used for quantitative
RT–PCR. Analysis was performed using an ABI PRISM 5700
Sequence Detection System (Applied Biosystems, Weiterstadt,
Germany). The genes were amplified with the Power SybrGreen
PCR Master Mix according to the manufacturer’s instructions.
Gene expression was quantified by the comparative Ct-Method,
normalising Ct-values to a housekeeping gene (b-actin) and
calculating the relative expression values. Each experiment was
repeated two times in duplicate. The following primers were used:
b-Actin: Actb 1498 f (AAGCCACCC-CACTTCTCTCTAA) and
actb-1570R (AATGCTATCACCTCCCCTGTGT), KLK10: KLK10_f1
ex (GTCCTGGTGGACCAGAGTTG) and KLK10_r1_ex (GAGCT
G-CTCTCCCTGAAGAA), KLK6: KLK6_f1 (GTG TGC TGG GGA
TGA GAA GT) and KLK6_r1 (GGG ATG TTA CCC CAT GAC AC)
(all from MWG Biotech, Ebersberg, Germany).
Western blotting
Cells were washed and lysed with LDS sample buffer (Invitrogen,
Karlsruhe, Germany). Proteins were electrophoresed under redu-
cing conditions on 4–12% acrylamide gels (Invitrogen, Karlsruhe,
Germany) and then transferred to a nitrocellulose membrane
(Hybond ECL, GE Healthcare, Munich, Germany). To block
nonspecific binding, the membrane was incubated overnight in
PBS with 0.1% Tween 20 (T-PBS) containing 5% BSA at 41C.
Subsequently, the membrane was incubated for 1h with the
antibody against KLK10 (1:1000, see (Petraki et al, 2001, 2002a,
2003)) or b-actin loading control (1:5000, no. ab6276, Abcam,
Cambridge, UK) in T-PBS and 5% BSA. After washing in T-PBS,
protein on the membrane was visualised using the ECL detection
kit (GE Healthcare, Munich, Germany) with a peroxidase-labelled
anti-mouse antibody for b-Actin (1:25000, no. NIF 825,
Amersham Pharmacia, Amersham, United Kingdom) and perox-
idase-labelled anti-rabbit antibody for KLK10 (1:5000, no. NIF
824, Amersham Pharmacia, Amersham, United Kingdom) as per
manufacturer’s instructions. Protein expression was measured by
AIDA evaluation software (Raytest, Straubenhardt, Germany) as
the ratio of KLK10-staining intensity to actin-staining intensity.
Boyden chamber assay
Invasion in vitro was measured in Boyden chamber assay
(no. 353097, BD Falcon, Heidelberg Germany). The PET membrane
had a pore size of 8mm with a pore density of 1.0 10
5cm
 2. Cells
were transfected using the above-mentioned protocol and
incubated for 48h. Cells were then trypsinised, counted and cell
suspensions of the two groups (5 10
5 cells per 250ml) were
transferred in 1% FCS medium onto the membrane. Then the
chambers were put in 24-well plates containing 10% FCS medium
and cultured for 72h. Cells infiltrated through the reconstituted
basement membrane and appeared on the outer surfaces. By HE
staining the number of the cells was counted microscopically.
Migration assays were repeated three times.
Statistical analysis
P-values were assigned using w
2 (Pearson) for the cross tables, the
log-rank test (Mantel–Cox) for the survival univariate analysis by
the Kaplan–Meier test, and the Cox regression analysis for
multivariate survival analysis. For statistical analysis ‘SPSS 13.0’
for Windows was used.
Table 1 Clinicopathological variables and KLK10 and KLK6 co-expres-
sion of the tumour cohort (n¼54)
All cases
Co-expression
Characteristics n (%) None/low Strong P-value
Age at diagnosis (years) 60.5 (range, 31–76)
Gender
Male 24 (44.4) 12 12 0.808
Female 30 (55.6) 16 14
Localisation
Head of pancreas 47 (87.0) 26 21 0.186
Tail of pancreas 7 (13.0) 2 5
Tumour stage
pT1 6 (11.1) 5 1 0.391
pT2 13 (24.1) 6 7
pT3 32 (59.3) 16 16
pT4 3 (5.5) 1 2
Nodal status
N0 22 (40.7) 12 10 0.565
N1 31 (57.4) 15 16
N2 1 (1.9) 1 0
Interaortocaval metastasis
Positive 7 (13.0) 4 3 0.764
Negative 47 (87.0) 24 23
Grade
G1 4 (7.4) 4 0 0.096
G2 38 (70.4) 17 22
G3 12 (22.2) 7 5
Residual tumour status
R0 41 (75.9) 25 16 0.017
R1 13 (24.1) 3 10
Perineural invasion
Yes 19 (35.2) 11 8 0.513
No 35 (64.8) 17 18
Perilymphatic invasion
Yes 24 (44.4) 11 13 0.429
No 30 (55.6) 17 13
Patients with strong immunohistochemical co-expression of KLK6 and KLK10 showed
a significant correlation with R1-Resection status (P¼0.017).
Table 2 Results of the serum ELISA showed no statistical significance
between diseases nor between different localisations
Median Mean
Diagnosis
(Localisation) KLK6 KLK10 KLK6 KLK10 P (log-rank)
Benign Tumours (n¼4) 12.4 2.1 10.3±7.8 1.4±1.8 n.s.
Inflammatory diseases
Bile duct (n¼1) 12.9 1.3
Gallbladder (n¼4) 13.1 2.1 14±2.2 2.3±0.67
Pancreas (n¼12) 10 2.0 7.7±5.7 2.4±0.79
Malignant tumours
Bile duct (n¼3) 8.1 1.3 7.2±4.7 1.2±0.31
Gallbladder (n¼3) 5.7 1.0 4.5±2.0 1.2±0.42
Pancreas (n¼8) 9.7 1.6 9.3±4.6 1.5±0.95
Normal (n¼65) 9.5 1.8 9.0±3.6 1.7±0.85
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Virtual subarray
Gene expression profiles of 19 patients with PDAC and normal
ductal cells from 13 individuals were generated (Pilarsky et al,
2008). We then constructed a virtual subarray to identify gene
expression changes of the 15 kallikreins. The nine probe sets
identified with the virtual subarray analysis represented six
differentially expressed genes (Table 3). Of these, KLK10 was
overexpressed whereas KLK3, 12, 13 and 15 were downregulated in
PDAC compared with microdissected normal ductal cells.
Upregulation of KLK10 was strong (Figure 1) compared with
normal individuals (P¼0.009). We also decided to consider KLK6
for further evaluation because upregulation was found in PDAC by
other groups (Iacobuzio-Donahue et al, 2003; Yousef et al, 2004).
Immunohistochemical expression of KLK6 and KLK10
In the endocrine pancreas, the immunohistochemistry for KLK6
and KLK10 showed strong staining in the endocrine cells of the
Langerhans’ islets and in scattered endocrine cells in connection
with pancreatic ducts and acinar cells.
The exocrine part of the pancreas displayed a cytoplasmic
expression in the small intercalated pancreatic ducts, the intra-
and inter-lobular pancreatic ducts, the main pancreatic duct and
the common bile duct. Staining was absent in the acinar cells
(Figure 2A and E). In the region of the ampulla of Vater in the
small intestine, a strong cytoplasmic, mostly supranuclear
immunoexpression was observed in the epithelium of the intestinal
crypts. The absorptive cells in the surface villous epithelium
showed a moderate cytoplasmic and brush border expression,
whereas goblet cells were mostly negative (Figure 2B).
The staining for KLK6 in primary PDAC showed a moderate to
strong expression in 91.5% of the cases, whereas it was only 64.4%
for KLK10.
KLK6 showed a diffuse cytoplasmic immunostaining in the
cancerous epithelium, whereas KLK10 mostly showed a patchy
expression, often with luminal pattern (Figure 2). Analysis of
immunohistochemistry revealed that patients with strong KLK6
and KLK10 co-expression had significant lower medium survival
time of 20 months (15.0–24.0) compared with patients without/
weak expression of these kallikreins (29 months (22.8–35.8))
(P¼0.031) (Figure 3). Neither KLK10 (P¼0.259) nor KLK6
(P¼0.452) expression could be correlated with survival alone.
We could further associate high KLK6 and KLK10 immunoreac-
tivity with R1-resection status (P¼0.017) (Table 1).
Cox regression analysis identified KLK10 and KLK6 co-expression
as an independent prognostic factor with a statistically significant
relationship to survival in PDAC (P¼0.043, RR 2.002) (Table 4).
Table 3 (A): Results of the GeneChip analysis. The upregulated genes (fold-change 42, Po5%) are listed in the upper part, the downregulated genes in
the lower part of the table; (B): Sequence-based and structure-based protein interaction prediction showed four possible interaction partners for KLK6
Probe set HGNC symbol Fold change P-value
A
Upregulated genes
KLK10@209792_s_at KLK10 5.2 o 0.01
KLK10@215808_at KLK10 1.6 0.01
Downregulated genes
KLK13@216670_at KLK13  1.7 0.01
KLK3@204583_x_at KLK3  6.6 0.03
KLK12@233586_s_at KLK12  9.4 o 0.01
KLK12@234316_x_at KLK12  10.1 o 0.01
KLK1@216699_s_at KLK1  10.2 o 0.01
KLK12@220782_x_at KLK12  10.5 o 0.01
KLK15@221462_x_at KLK15  15.3 o 0.01
B
Protein 1 Predicted partner Also known as Function Compartment
KLK6 SERPINA3 a-1 antiproteinase DNA-binding, endopeptidase
inhibitor activity,
inflammatory response
Extracellular, intracellular,
nucleus
SERPINC1 AT III Blood coagulation Extracellular region
SERPINF2 Pigment epithelium-derived
factor
Endopeptidase inhibitor activity,
protein-binding,
acute phase response
Extracellular region
SNCA Synuclein Anti-apoptosis, central nervous system,
development, protein binding
Cytoplasm
KLK10 No interaction partner found
2000.00
1500.00
1000.00
500.00
0.00
Normal ductal epithelia Pancreatic cancer
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Figure 1 Results of the GeneChip analysis. KLK10 showed a marked
upregulation in pancreatic cancer samples compared with normal
individuals (P¼0.009).
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Using ELISA immunoassays developed in-house, we tested KLK6
and KLK10 serum levels in patients with malignant, inflammatory
and benign diseases; additionally there was a panel of healthy
patients.
There was no significant correlation of KLK6 and KLK10 serum
levels with survival of the patients. Also, there was no statistical
significance between healthy donors and patients with PDAC nor
between different localisations of inflammatory, benign and
malignant diseases of the pancreatico-biliary tract (Table 2).
Protein interaction prediction
To find potential interaction partners for KLK6 and 10, which
might explain poor survival, we used two different computational
methods: the structure- and the sequence-based protein interac-
AB
CD
EF
Figure 2 Immunohistochemical staining of PDAC samples. Moderate KLK6 immunoexpression in pancreatic ducts (arrow) and strong expression in
Langerhans’ islets (arrowhead) no staining in acini ( 100) (A). Strong KLK10 immunoexpression in the crypts of the intestinal epithelium of the ampulla of
Vater ( 100) (B). Strong KLK6 immunoexpression in pancreatic adenocarcinomas ( 200) (C and D). Moderate KLK10 immunoexpression in pancreatic
adenocarcinomas ( 200) (E). Strong KLK10 immunoexpression in Langerhans’ islets (arrow), absence of expression in pancreatic adenocarcinoma
(arrowhead) ( 200) (F).
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Figure 3 The survival curve shows a lower medium survival time of 20
months (15.0–24.0) in the subgroup of patients with strong KLK6 and
KLK10 co-expression compared with patients without/weak expression of
these kallikreins (29 months (22.8–35.8)) (P¼0.031).
Table 4 Cox regression model, including conventional variables and
co-expression of KLK6 and KLK10 in all cases (n¼54)
Relative risk 95% CI P-value
Co-expression KLK6/KLK10 2.022 1.021–4.006 0.043
Resection status 0.571 0.247–1.321 0.190
Grading 1.964 1.030–3.746 0.040
pT stage 0.498 0.310–0.801 0.004
Nodal status 1.814 0.937–3.513 0.077
Metastases 0.545 0.177–1.679 0.290
Co-expression is a strong independent prognostic factor for survival in patients with
PDAC (P¼0.043).
Kallikreins in pancreatic cancer
FR u ¨ckert et al
1488
British Journal of Cancer (2008) 99(9), 1484–1492 & 2008 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
stion prediction. By means of these methods we could identify four
potential interaction partners for KLK6: a-1 antiproteinase, AT III,
pigment epithelium-derived factor and synuclein (Table 3).
However, no additional interaction partner for KLK10 other than
the already described could be identified (Dawelbait et al, 2007).
Expression of KLK10 and KLK6 in pancreatic cancer cell
lines
To evaluate expression of KLK10 and KLK6 in established cell lines
we conducted a qRT–PCR. Capan-2, Panc89 and AsPC-1 cell lines
displayed the highest KLK10 expression. For KLK6 the cell lines
Capan-2, Mia PaCa-2 and AsPC-1 showed a good expression. Like
in immunohistochemistry of native tumour, KLK6 expression in
cell lines was more distinct than that of KLK10 (Figure 4).
Gene silencing of KLK10 in AsPC-1 cells
To elucidate the relevance of dysregulations of KLK10 for
carcinogenesis, we established a siRNA assay. For this purpose,
we used the human pancreatic cancer cell line AsPC-1. This cell
line showed detectable KLK10-expression as well as KLK6-
expression (Figure 4).
Cells were transfected with two KLK10 sequences, KLK10.1 and
KLK10.2. Untreated cells and cells transfected with unspecific
siRNA served as a negative control. As shown in Figure 5 the
expression of KLK10 was strongly inhibited compared with
controls in RT–PCR (Po0.001). The same holds true for protein
synthesis in western blot (P¼0.025). b-actin levels showing equal
quantities of protein were loaded (Figure 5); all experiments were
repeated four times. Because transfection with KLK10.1 showed the
best inhibition of protein synthesis we chose this siRNA for our
further studies. To examine off-target gene-silencing in our cells,
we used the BLAST database (www.ncbi.nlm. nih.gov/BLAST) to
search the human genome for any complementary sequences with
at least 11 contiguous nucleotides matching the RNAi sites we used.
No gene appeared to have sequence similarity. Transfection of
AsPC-1 cells with KLK10.2 siRNA did not change the KLK6
expression levels as measured qRT–PCR (see Supplementary Data 1).
Migration assay
AsPC-1 cells transfected with KLK10.1 siRNA showed a significant
decrease in cell motility compared with the GFP-transfected cells.
Although only 636 cells (±285) could be isolated from the
membrane in KLK10 knockout cells, it was 1189 (±508) in the
control group (P¼0.05) (Figure 5).
DISCUSSION
KLK10 and KLK6 are among the most highly and specifically
overexpressed genes in pancreatic cancer compared with normal
and benign pancreas tissues (Grutzmann et al, 2003; Iacobuzio-
Donahue et al, 2003; Yousef et al, 2004).
Our study confirmed a marked overexpression of KLK10 in
PDAC by means of a virtual subarray. Immunohistochemistry in
native tumour tissue could prove not only an intense expression
for KLK10 in 64.4% of the malignant cells, but also for KLK6 in
91.5%. Both proteins were located in the cytoplasm, from where
they are likely to be secreted (Borgono et al, 2004).
Co-expression of different kallikreins, similar to the situation
found in our study, was already reported in skin and different
glands. In these tissues the kallikreins can act independently, but
also together as part of proteolytic cascades (Petraki et al, 2002b;
Borgono and Diamandis, 2004). The latter seems to be an
important mechanism in pancreatic cancer, because expression
of KLK10 itself could not be associated with poor survival in
PDAC, whereas the co-expression of both kallikreins was
significantly associated with poor survival and an R1-resection
status, which is an indirect sign for infiltrative and aggressive
growth. In multivariate analysis, the co-expression of KLK10 and
KLK6 was also an independent risk factor for survival.
It is most interesting, in which ways kallikreins affect cellular
signalling and thereby contribute to cancer progression. It was
already reported that kallikreins influence communication
between malignant cells and their environment by degradation
of extracellular matrix and thereby facilitate tumour invasion
and metastasis (Borgono and Diamandis, 2004). In case of
KLK6, degradation of fibrinogen, laminin, fibronectin and collagen
types I and IV are documented (Bernett et al, 2002; Magklara et al,
2003). This cleavage of fractions of the ECM might be of
specific importance in pancreatic carcinoma, which is a tumour
type with a very high content of stromal tissue (Pilarsky et al,
2008). In contrast, functional data on KLK10 are very limited.
Although Zhang et al (2006) suggested, that KLK10 was not
even an active protease, it was stated in the same report
that neither the protein relevant for conversion of KLK10 into its
active form nor the physiological substrates for KLK10 are known.
So, the importance of KLK10 in tumour progression remains
unclear.
It therefore seems crucial to further pinpoint some of the
components, which might be responsible for the pathophysiolo-
gical effect of KLK10. To find possible interaction partners for both
kallikreins we used the in silico method of protein interaction
prediction. By means of this method we could identify four
potential interaction partners for KLK6. Although a-1 antiprotei-
nase seems to be an inhibitor for KLK6 action, the interaction with
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Figure 4 A qRT–PCR of different established pancreatic cancer cells
lines showed Capan-2 and AsPC-1 with relevant KLK10-expression (A).
KLK6-expression was high in nearly all measured cell lines (B).
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sAT III shows a branching between kallikreins and blood
coagulation cascade, as already reported earlier (Borgono et al,
2004). Another interaction partner was pigment epithelium-
derived factor (PEDF), which is the major circulating inhibitor
of plasmin. With this interaction, PEDF is linked to the
plasminogen activator/plasmin system, which is one of the main
protease systems involved in tumour cell invasion and metastasis
(Hayashido et al, 2007). Only recently PEDF was also identified as
a key inhibitor of stromal vasculature in the mural pancreas.
In vivo androgen ablation increased PEDF in human cancer
biopsies, which might also be an indirect sign for the interaction of
the androgen-responsive kallikrein family and PEDF (Doll et al,
2003). The interaction between KLK6 and PEDF seems highly
significant and studies are under way which will further evaluate
this topic. Another interaction partner we found is synuclein,
which integrates presynaptic signalling and membrane trafficking
in neurons. The high expression of KLK6 might thereby play an
important role in various pathologic processes of pancreatic
cancer.
Although a specific interaction partner for KLK10 could not be
found, our study implies that it might have a role in the
pathophysiology of PDAC. To ascertain the contribution of
KLK10 to pancreatic cancer microenvironment, we used siRNA-
mediated gene-silencing (Hammond et al, 2000). AsPC-1 cells,
which inherently express high levels of KLK10 mRNA, were
transfected with specific siRNA. We could not observe an effect on
proliferation or apoptosis in KLK10-silenced cells (data not
shown). But KLK10-suppressed clones had markedly reduced cell
motility in the Boyden chamber assay. The number of cells
migrating through the membrane along an FCS-gradient dropped
more than 50%. This is highly significant, as KLK6 was also shown
to reduce cell motility (Ghosh et al, 2004).
Although high expression in pancreatic carcinoma indicates that
KLK6 and 10 could be promising tumour markers, we could not
assess the use of KLK6 and KLK10 as serum biomarkers in PDAC.
The serum levels of both proteins showed no significant
differences between patients with PDAC and healthy donors. In
addition, the serum concentrations were not able to predict the
localisation of malignant lesions in the pancreatico-biliary tract.
This circumstance can be because of the mainly local action of the
kallikreins or fast degradation. Probably future studies including
more patients can prove a use for KLK6 or KLK10 as tumour
biomarkers in PDAC.
In conclusion, this study shows that KLK10 and KLK6
co-expression has an unfavourable influence on the survival in
patients with PDAC and was significantly associated with R1
80.00
120.00
100.00
80.00
60.00
40.00
20.00
0.00
60.00
40.00
20.00
0.00
hk10.1 hk10.2 Neg. control Vehicle
hk10.1 hk10.1 hk10.2 Neg. control Neg. control Vehicle
K
L
K
1
0
-
e
x
p
r
e
s
s
i
o
n
/
a
c
t
i
n
-
e
x
p
r
e
s
s
i
o
n
D
e
l
t
a
-
c
T
 
K
L
K
1
0
(
%
)
C
e
l
l
 
n
u
m
b
e
r
2500.00
2000.00
1500.00
1000.00
500.00
0.00
kDa
1
0
.
1
1
0
.
2
N
e
g
.
 
c
o
n
t
r
o
l
 
2
N
e
g
.
c
o
n
t
r
o
l
 
1
V
e
h
i
c
l
e
25
-Actin
KLK10
12 345
Figure 5 AsPC-1 cells were transfected with two KLK10-sequences, KLK10.1 and KLK10.2. Transfection resulted in a strong downregulation of KLK10
protein synthesis in the western blot. Cell lysates of KLK10.1- and KLK10.2-transfected cells showed nearly no staining (lanes 1 and 2) compared with the
controls (lanes 3–5) (A). Statistical analysis showed a statistical downregulation of the transfected group compared with the control group (P¼0.025) (B).
The same holds true for gene expression in RT–PCR (Po0.001) (C). The Boyden chamber migration assay: Invasion in vitro was measured as described in
‘Materials and methods’. Statistical analysis showed that KLK10.1-transfected cells had a significant decrease in cell motility compared with the controls
(P¼0.05) ( 200) (D). Only few KLK10.1-transfected AsPC-1 cells migrated through the membrane (arrow) (E). The control group displayed normal cell
migration (arrows) (F).
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sresection status. This effect might be mediated by direct or indirect
interaction of the two kallikreins. The pathophysiological mechan-
isms are most likely degradation of the extracellular matrix and
interaction with angiogenic factors by KLK6, whereas KLK10
augments cell motility. However, our findings suggest a high
complexity of interactions between the kallikreins, which leaves it
difficult to generally make statements about properties of single
kallikreins.
It seems very promising to find out more about the
physiological role of KLK10. Consequently, it might be possible
to use inhibitors of kallikreins to disrupt interactions between the
tumour and its environment and thereby reduce disease progres-
sion in patients with pancreatic cancer.
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